Get started
Author

Cheng Ean Chee

Observed names: C CHEE, C. Cheng Ean, C.E. Chee, Chee Cheng Ean, Chee, Cheng E., Chee, Cheng Ean, Cheng E. Chee, Cheng E Chee, Cheng E. Chee, Cheng Ean CHEE, Cheng Ean Chee (13254607)
Observed institutions: Mayo Clinic, University College London Hospitals NHS Foundation Trust, National University of Singapore, Nicosia General Hospital, London School of Hygiene & Tropical Medicine, National University Cancer Institute, Singapore, Louis Stokes Cleveland VA Medical Center, University Hospitals Seidman Cancer Center, National University Hospital, National University Health System, Case Comprehensive Cancer Center, Mayo Clinic Comprehensive Cancer Center (Minnesota), Cancer Science Institute of Singapore, Case Western Reserve University
ORCID: 0000-0003-2385-7712
Observed ORCIDs: 0000-0003-2385-7712, 0000-0002-3435-0151
OpenAlex ID: A5045076272
The Role of Autophagy in Cancer: Therapeutic Implications
2011 · Zhineng J. Yang, Cheng E. Chee, et al. · Molecular Cancer Therapeutics · 1,241
PDF
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study
2014 · Cheng E. Chee, Aneel A. Ashrani, et al. · Blood · 215
Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
2018 · Yue Zhao, Timothy Wai Ho Shuen, et al. · Gut · 214
PDF
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines
2021 · Glenn K Bonney, Claire Alexandra Chew, et al. · The Lancet. Gastroenterology & hepatology · 194
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
2020 · Daniel V T Catenacci, Yoon-Koo Kang, et al. · The Lancet Oncology · 192
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2020 · Debashis Sarker, Ruth Plummer, et al. · Clinical Cancer Research · 189
PDF
Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
2022 · Margaret A. Tempero, Uwe Pelzer, et al. · Journal of Clinical Oncology · 158
PDF
Autophagy modulation for cancer therapy
2011 · Zhineng J. Yang, Cheng E. Chee, et al. · Cancer Biology & Therapy · 140
PDF
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
2019 · Ronan J. Kelly, Jeeyun Lee, et al. · Clinical Cancer Research · 135
PDF
Making sense of adjuvant chemotherapy in colorectal cancer
2019 · Gloria H. J. Chan, Cheng E. Chee · Journal of Gastrointestinal Oncology · 100
PDF
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2021 · Ayumi Hashimoto, Debashis Sarker, et al. · Clinical Cancer Research · 99
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
2021 · T. Yoshino, G. Argilés, et al. · Annals of Oncology · 96
PDF
Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts
2008 · Cheng E. Chee, David P. Steensma, et al. · American Journal of Hematology · 82
PDF
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
2013 · Cheng Ean Chee, Smitha Krishnamurthi, et al. · The Oncologist · 77
PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases
2020 · Guowei Kim, Hon Lyn Tan, et al. · Clinical Cancer Research · 67
Pitfalls in the Diagnosis of Primary Amyloidosis
2010 · Cheng E. Chee, Martha Q. Lacy, et al. · Clinical Lymphoma Myeloma & Leukemia · 59
A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).
2018 · Johanna C. Bendell, Yung-Jue Bang, et al. · Journal of Clinical Oncology · 57
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
2009 · Cheng E. Chee, Shaji Kumar, et al. · Blood · 52
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
2019 · Min Thura, Abdul Qader Al-Aidaroos, et al. · Nature Communications · 50
PDF
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model
2021 · Yue Zhao, Jiaxu Wang, et al. · Hepatology · 49
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions
2024 · David Johnson, Cheng Ean Chee, et al. · Cancer Treatment Reviews · 48
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
2023 · Byoung Chul Cho, Chao-Hua Chiu, et al. · Lung Cancer · 46
PDF
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
2016 · Dexter Yak Seng Chan, Nicholas Li-Xun Syn, et al. · Journal of Gastrointestinal Surgery · 46
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
2022 · Daryl K. A. Chia, Raghav Sundar, et al. · Annals of Surgical Oncology · 45
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
2024 · Priyadarshini S. Pathak, Gloria Chan, et al. · American Society of Clinical Oncology Educational Book · 42
Works count: 211
Citation count: 4,470
H-index: 30
I10-index: 51
Year
Topic
Type